Valuation : Adaptive Biotechnologies Corporation

Market Cap 3.87B 3.33B 3.13B 2.86B 5.35B 366B 5.37B 37.16B 14.36B 188B 14.55B 14.23B 598B P/E 2026 *
-44.6x
P/E 2027 * -137x
Enterprise Value 3.82B 3.28B 3.09B 2.82B 5.27B 361B 5.29B 36.6B 14.15B 185B 14.33B 14.02B 589B EV / Sales 2026 *
13x
EV / Sales 2027 * 10.5x
Free-Float
97.94%
Yield 2026 *
-
Yield 2027 * -
1 day-1.48%
1 week-2.57%
Current month-2.57%
1 month-2.61%
3 months+43.67%
6 months+63.39%
Current year+49.51%
1 week 23.84
Extreme 23.84
25.36
1 month 23.84
Extreme 23.84
26.87
Current year 12
Extreme 12
26.87
1 year 12
Extreme 12
26.87
3 years 2.28
Extreme 2.28
26.87
5 years 2.28
Extreme 2.28
39.79
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Executive Officer 51 08/09/2009
Director of Finance/CFO 42 08/04/2024
President 54 01/02/2018
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 01/02/2013
Director/Board Member 70 01/12/2013
Date Insider Type Main position Quantity % Market Cap. Importance
31/08/26 Don

Director

-12,539 0.0079%
26/08/26 Sell

Director

-9,615 0.0060%
18/08/26 Exercice

Director

60,664 0.0379%
Change 5-day change 1-year change 3-year change Capi.($)
-1.48%-2.57%+88.95%+285.40% 3.87B
-2.62%+7.59%+253.01%+51.55% 3.98B
-1.13%-1.53%+31.14%+67.90% 3.42B
-1.03%+1.54%+268.16%+515.98% 2.63B
+0.05%-5.14%-27.77%-29.70% 2.11B
-0.67%+10.28%+54.60% - 1.75B
-2.87%-4.19%+191.63%-33.99% 1.09B
-1.57%-6.55%+21.47%+43.05% 1.06B
+6.40%-1.93%+9.03%+54.34% 648M
+0.72%-0.93%-32.69%-2.81% 531M
Average -0.39%+0.01%+85.75%+105.75% 2.11B
Weighted average by Cap. -1.15%+0.98%+114.77%+148.91%

Financials

2026 *2027 *
Net sales 293M 252M 237M 217M 405M 27.73B 406M 2.81B 1.09B 14.2B 1.1B 1.08B 45.24B 359M 308M 290M 265M 495M 33.91B 497M 3.44B 1.33B 17.36B 1.35B 1.32B 55.31B
Net income -85.78M -73.77M -69.38M -63.34M -118M -8.11B -119M -823M -318M -4.15B -322M -315M -13.23B -27.55M -23.69M -22.29M -20.34M -38.05M -2.61B -38.17M -264M -102M -1.33B -103M -101M -4.25B
Net Debt -58.99M -50.73M -47.72M -43.56M -81.47M -5.58B -81.73M -566M -219M -2.86B -222M -217M -9.1B -104M -89.3M -83.99M -76.67M -143M -9.82B -144M -996M -385M -5.03B -390M -381M -16.02B
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
05/09/26 $24.28 -1.18% 1,404,316
03/09/26 $24.57 -0.36% 2,161,036
02/09/26 $24.66 +1.31% 1,623,149
01/09/26 $24.34 -2.33% 1,621,010
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
24.28USD
Average target price
25.07USD
Spread / Average Target
+3.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADPT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!